- Investing Ideas
- Australian Pharmaceuticals & Biotech Healthy potentially undervalued
Australian Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Clinuvel Pharmaceuticals
Market Cap: AU$445.3m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$8.93
7D
-0.3%
1Y
-14.1%
CSL
Market Cap: AU$44.8b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$92.59
7D
-5.1%
1Y
-61.9%
Trajan Group Holdings
Market Cap: AU$53.4m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.34
7D
1.5%
1Y
-53.1%
Radiopharm Theranostics
Market Cap: AU$69.1m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.019
7D
-9.5%
1Y
-26.9%